24/7 Market News Snapshot 20 October, 2025 – Verrica Pharmaceuticals Inc. Common Stock (NASDAQ:VRCA)
DENVER, Colo., 20 October, 2025 (www.247marketnews.com) – (NASDAQ:VRCA) are discussed in this article.
Verrica Pharmaceuticals Inc. is making significant strides within the biotechnology sector, showcasing both an impressive surge in stock value and advancing critical regulatory steps for its innovative treatments. The company’s stock opened at $4.17 and experienced a remarkable increase, trading at $5.134, reflecting a notable gain of 23.71% after closing at $4.15. This surge, driven by robust trading activity with over 1.28 million shares exchanged, indicates a burgeoning investor interest, positioning Verrica as a stock to watch within the market.
In a pivotal development, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has determined that the existing clinical data from Verrica’s Phase 3 trials in the U.S. and Japan is sufficient to support a Marketing Authorization Application (MAA) for its groundbreaking product, YCANTH®. This treatment offers a new solution for molluscum contagiosum, a contagious skin disease affecting millions.
The CHMP’s endorsement negates the need for additional Phase 3 studies, allowing the company to commence preparations for a filing slated for late 2026. Jayson Rieger, PhD, MBA, the President and CEO of Verrica, expressed enthusiasm for this regulatory alignment, emphasizing the significant unmet needs in the European market for patients suffering from molluscum.
YCANTH® is a proprietary drug-device combination that employs a GMP-controlled formulation of cantharidin, delivered via an easy-to-use applicator. It is already approved in the U.S. for patients ages two and older, marking it as the first therapeutic specifically targeting molluscum. As Verrica progresses towards its European approval, the company remains dedicated to enhancing patient care through innovative solutions in dermatology, affirming its commitment to addressing urgent medical needs in skin diseases.
Related news for (VRCA)
- Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union
- Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
- 24/7 Market News Snapshot 07 October, 2025 – Verrica Pharmaceuticals Inc. Common Stock (NASDAQ:VRCA)